Comprehensive Center for Precision Oncology (C2PO), Centro de Investigação Translacional em Oncologia (CTO), Departamento de Radiologia e Oncologia, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil.
Comprehensive Center for Precision Oncology (C2PO), Centro de Investigação Translacional em Oncologia (CTO), Departamento de Radiologia e Oncologia, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil.
Clinics (Sao Paulo). 2024 Aug 28;79:100479. doi: 10.1016/j.clinsp.2024.100479. eCollection 2024.
To identify somatic mutations in tumors from young women with triple-negative or luminal breast cancer, through targeted sequencing and to explore the cancer driver potential of these gene variants.
A customized gene panel was assembled based on data from previous sequencing studies of breast cancer from young women. Triple-negative and luminal tumors and paired blood samples from young breast cancer patients were sequenced, and identified gene variants were searched for their driver potential, in databases and literature. Additionally, the authors performed an exploratory analysis using large, curated databases to evaluate the frequency of somatic mutations in this gene panel in tumors stratified by age groups (every 10 years).
A total of 28 young women had their tumoral tissue and blood samples sequenced. Using a customized panel of 64 genes, the authors could detect cancer drivers in 11/12 (91.7 %) TNBC samples and 11/16 (68.7 %) luminal samples. Among TNBC patients, the most frequent cancer driver was TP53, followed by NF1, NOTCH1 and PTPN13. In luminal samples, PIK3CA and GATA3 were the main cancer drivers, and other drivers were GRHL2 and SMURF2. CACNA1E was involved in both TN and luminal BC. The exploratory analysis also indicated a role for SMURF2 in luminal BC development in young patients.
The data further indicates that some cancer drivers are more common in a specific breast cancer subtype from young patients, such as TP53 in TNBC and PIK3CA and GATA3 in luminal samples. These results also provide additional evidence that some genes not considered classical cancer-causing genes, such as CACNA1E, GRHL2 and SMURF2 might be cancer drivers in this age group.
通过靶向测序鉴定年轻女性三阴性或 luminal 乳腺癌肿瘤中的体细胞突变,并探索这些基因突变的致癌潜力。
根据先前对年轻女性乳腺癌测序研究的数据,设计了一个定制的基因panel。对年轻乳腺癌患者的三阴性和 luminal 肿瘤及其配对血样进行测序,并在数据库和文献中寻找有潜在致癌性的基因突变。此外,作者还使用大型、精心整理的数据库进行了探索性分析,以评估该基因panel 在按年龄组分层的肿瘤中(每 10 年)体细胞突变的频率。
共有 28 名年轻女性的肿瘤组织和血液样本进行了测序。使用 64 个基因的定制 panel,作者在 12 例三阴性乳腺癌样本中的 11 例(91.7%)和 16 例 luminal 样本中的 11 例(68.7%)中检测到了致癌驱动基因。在三阴性乳腺癌患者中,最常见的致癌驱动基因是 TP53,其次是 NF1、NOTCH1 和 PTPN13。在 luminal 样本中,PIK3CA 和 GATA3 是主要的致癌驱动基因,其他驱动基因是 GRHL2 和 SMURF2。CACNA1E 参与了 TN 和 luminal BC。探索性分析还表明,SMURF2 在年轻患者的 luminal BC 发展中也有作用。
这些数据进一步表明,一些致癌驱动基因在年轻患者的特定乳腺癌亚型中更为常见,如三阴性乳腺癌中的 TP53 和 luminal 样本中的 PIK3CA 和 GATA3。这些结果还提供了额外的证据,表明一些未被认为是经典致癌基因的基因,如 CACNA1E、GRHL2 和 SMURF2,可能是该年龄段的致癌驱动基因。